Drug Pricing Challenges and Navigating the IRA

How to price a bio/pharmaceutical drug is one of the most complex topics for pharmaceutical executives, as there are many factors to consider. Alice Valder Curran, life sciences regulatory expert and partner, Hogan Lovells LLP, reveals the following to Pharmaceutical Executive® in this exclusive Pharm Exec Podcast interview:

• The biggest drug pricing challenges today
• Current efforts to lower drug pricing
• Whatcompanies should consider as it relates to drug pricing from a legal perspective
• The status of the Inflation Reduction Act (IRA), specifically what should companies be watching for
• Potential impact on companies from the IRA
• IRA milestones we will be seeing through the end of the year
• Drug pricing recommendations (from a legal perspective)

About the speaker

Alice Valder Curran is a life sciences regulatory expert and partner at Hogan Lovells with a particular emphasis on pharmaceutical pricing and market access.As an influential policy advocate before Congress and the Executive Branch, Curran has built a market-leading practice serving drug developers in the areas of drug pricing, regulatory innovation, and market access. The Financial Times recognized her in its awards, “Most Innovative Legal Practitioner,” for her work developing the multiple best prices reporting option, which was codified by CMS in regulation. With Congress’ recent adoption of significant changes to drug pricing regulation, she is a sought-after advisor on the economic and policy implications of the IRA.

About the Pharm Exec Podcast

The editors of Pharmaceutical Executive bring you the latest commercial insights to master the science of success. Podcast episodes examine current trends, key conferences, and critical topics in the bio/pharmaceutical industry.

Listen to this podcast on SoundCloud, Spotify, Google Podcasts, or Apple Podcasts.